The State Licensing Authority of Uttarakhand has granted license for Coronil tablet to be used as supporting measure in the management of COVID-19 without claiming cure following the advice of a review committee set up by the AYUSH ministry, the Lok Sabha was informed on Friday.
Minister of State for Health Bharati Pravin Pawar, in a written reply, said the Interdisciplinary Technical Review Committee (ITRC) setup by the AYUSH ministry reviewed the application submitted by the Patanjali Research Foundation Trust for updating the AYUSH license for Divya Coronil tablet from immunity booster' to medicine for COVID-19'.
The committee suggested that the tablet may be used as supporting measure in Covid management, she said.
The application titled Updating AYUSH license for Divya Coronil tablet from Immunity booster to Medicine for COVID-19' submitted by Patanjali Research Foundation Trust, Haridwar, Uttarakhand to this Ministry, was placed before the ITRC on October 27, 2020 for examination of the applications/claims on patent and propriety (P&P) ASU&H medicines with new indications or repurposing of licensed P&P, ASU&H medicines for COVID-19, Pawar said in her reply.
"The ITRC reviewed the study and it was suggested that it may be used as a supporting measure in Covid. The State Licensing Authority was also informed that Coronil tablet may be used as supporting measure in the management of COVID-19 without claiming cure," she added.
The MoS was responding to a question on whether the Centre has upgraded the license for Patanjali Ayurved's Coronil from an immunity booster to a supporting measure in treating COVID-19 and the details thereof along with the data/studies based on which such an upgrade was approved.
Explaining the rules under which such an approval was granted, Pawar said the regulatory provisions for granting license and approval of Ayurvedic, Siddha, Unani and Homoeopathy drugs are prescribed under the Drugs and Cosmetics Act, 1940 and Rules 1945.
The Section 3(a) and Section 3(h) define all Ayurvedic, Siddha, Unani medicines intended for internal or external use for or in the diagnosis, treatment, mitigation or prevention of diseases or disorder in human beings or animals, and manufactured exclusively in accordance with the formulae described in, the authoritative books of Ayurvedic, Siddha and Unani Tibb systems of medicine, specified in the First Schedule.
"The State Licensing Authority Uttarakhand has granted license of drug Coronil after examination of the application submitted by the applicant. The State Licensing Authority Ayurveda, Government of Uttarakhand was informed that Coronil tablet may be used as supporting measure in the management of COVID-19 without claiming cure," the minister added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)